Article

Epithelial delay, pain are concerns with new NSAID

Fort Lauderdale, FL-Administration of nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) for epithelial healing and pain control resulted in delayed healing in patients who had undergone surface ablation, according to a report by Marguerite B. McDonald, MD, FACS, and William Trattler, MD, that was presented at the annual meeting of the Association for Research and Vision in Ophthalmology.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.